RICT 2014
Conferences > Archives > RICT 2014

Confirmed Speakers


Confirmed Speakers

Ehrlich Prize Winner
Natural Antitumor Macrolides Acting on Tubulin: Synthesis and Functional Exploration
Prof. Karl-Heinz ALTMANNProf. Karl-Heinz ALTMANN
(SCS DMCCB & SWISS FEDERAL INSTITUTE OF TECHNOLOGY, Zurich, Switzerland)

Read more
PDE10A Inhibitors as Potential Treatments for Schizophrenia
Dr Jose Manuel BARTOLOMEDr Jose Manuel BARTOLOME
(JANSSEN RESEARCH & DEVELOPMENT, Toledo, Spain)

Read more
Recent Advances in Predicting Cardiac Risk during Drug Development
Dr Arthur BROWNDr Arthur BROWN
(CHANTEST, Cleveland, United States)

Read more
Excursions in Uncharted Structural Space
Prof. Erick M. CARREIRAProf. Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

Read more
Novel Imidazoles as Selective TAAR1 Partial Agonists for the Treatment of Psychiatric Disorders
Dr Giuseppe CECEREDr Giuseppe CECERE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Read more
Exploiting the Information Rich Output of SPR Biosensor Technology in Drug Discovery – From Target Evaluation to Fragment and Lead
Prof. Helena DANIELSONProf. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

Read more
Translational Biophysics: Using Biophysical Data in Medicinal Chemistry
Dr Matthias FRECHDr Matthias FRECH
(MERCK, Darmstadt, Germany)

Read more
Use of Peptides to Modulate Protein-Protein Interactions
Prof. Ernest GIRALTProf. Ernest GIRALT
(INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB), Barcelona, Spain)

Read more
Discovery and Optimisation of a Novel Series of EZH2 Inhibitors, Challenges and Clinical Perspectives
Dr Jean-Christophe HARMANGEDr Jean-Christophe HARMANGE
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Read more
Molecular Basis of Ligand Dissociation from GPCRs – a Molecular Dynamics and Mutagenesis Study on the Adenosine A2A Receptor
Dr Laura HEITMANDr Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

Read more
The Design and Optimisation of Selective Protein Kinase C Theta Inhibitors for the Treatment of Autoimmune Diseases
Dr Juan-Miguel JIMENEZDr Juan-Miguel JIMENEZ
(VERTEX PHARMACEUTICALS, Abingdon, United Kingdom)

Read more
Cell Identity Loss in Cancer: a Source of New Biomarkers and Therapeutic Targets
Dr Saadi KHOCHBINDr Saadi KHOCHBIN
(JOSEPH FOURIER UNIVERSITY, Grenoble, France)

Read more
The Lab Oddity Prevails - Discovery of pan-CDK Inhibitor BAY 1000394 (Roniciclib) for the Treatment of Cancer
Dr Ulrich LÜCKINGDr Ulrich LÜCKING
(BAYER HEALTHCARE, Berlin, Germany)

Read more
Targeting BAX for Cancer Therapy: from Computer Screen to Mouse
Dr Luciana MARINELLIDr Luciana MARINELLI
(UNIVERSITY OF NAPOLI, Napoli, Italy)

Read more
Polar Units and Dipolar Interactions Modulating, Conformation, Lipophilicity, and other Physicochemical Properties
Prof. Klaus MÜLLERProf. Klaus MÜLLER
(F. HOFFMANN-LA ROCHE, Switzerland)

Read more
Specific Antidotes for Dabigatran: Structure-Guided Affinity Optimisation and Functional Characterisation
Dr Herbert NARDr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)

Read more
High-Throughput Chemical Microarray SPR: The Biophysical Tool for Fragment Based Screening in Drug Discovery
Dr Thomas NEUMANNDr Thomas NEUMANN
(GRAFFINITY PHARMACEUTICALS, Illkirch, France)

Read more
Discovery of TAK-632: Pan-RAF Inhibitor with Potent Antitumor Activity against BRAF and NRAS Mutant Melanomas
Dr Masanori OKANIWADr Masanori OKANIWA
(TAKEDA PHARMACEUTICAL COMPANY, Kanagawa, Japan)

Read more
Chemical Probes for Epigenetics
Dr Dafydd OWENDr Dafydd OWEN
(PFIZER, Cambridge, United States)

Read more
Design and Applications of Protein Epitope Mimetics
Prof. John ROBINSONProf. John ROBINSON
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

Read more
Pseudo-Natural Product Synthesis and Drug Applications
Prof. Hiroaki SUGAProf. Hiroaki SUGA
(UNIVERSITY OF TOKYO, Tokyo, Japan)

Read more
2-Clips Peptides: A Novel Class of Biopharmaceuticals
Prof. Peter TIMMERMANProf. Peter TIMMERMAN
(PEPSCAN THERAPEUTICS, Lelystad, The Netherlands)

Read more
Genotoxicity Screening can guide Lead Optimisation and Reduce Late Stage Attrition
Prof. Richard WALMSLEYProf. Richard WALMSLEY
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

Read more
Strategies to Target Protein-Protein Interactions: from Discovery to Clinical Development
Prof. Shaomeng WANGProf. Shaomeng WANG
(UNIVERSITY OF MICHIGAN, Michigan, United States)

Read more

Short Communications

Identification of Cell-penetrating Compounds and their Use for Intracellular Delivery of Cathepsin D Inhibitors
Prof. Muriel AMBLARDProf. Muriel AMBLARD
(CNRS-UNIVERSTY OF MONTPELLIER I, Montpellier, France)

Read more
Silicon-containing Tetrahydrocyclopenta[c]acridine Derivatives as CDKs Inhibitors: Design, Organometallic Synthesis, Metabolic Stability and Optimisation
Prof. Philippe BELMONTProf. Philippe BELMONT
(UNIVERSITY PARIS DESCARTES, Paris, France)

Read more
Innovative Fluorescent-Based Approaches to GPCR Screening and Functional Architecture Studies
Prof. Dominique BONNETProf. Dominique BONNET
(UNIVERSITY OF STRASBOURG, Illkirch, France)

Read more
Combining Organic Synthesis, Software Development and Biochemistry for the Design and Discovery of Prolyl oligopeptidase Inhibitors
Prof. Nicolas MOITESSIERProf. Nicolas MOITESSIER
(MCGILL UNIVERSITY, Montreal, Canada)

Read more

Organised by

With the support of

Major Sponsor

Media Partner

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys